Technical advances of radiation therapy for thymic malignancies

Journal of Thoracic Oncology

Volumn 5, Issue 10 SUPPL. 4, 2010, Pages

  Gomez, Daniel ^a   Komaki, Ritsuko ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

3D conformal therapy; 4D treatment planning; Adaptive radiation therapy; Intensity modulated radiation therapy; Proton therapy; Radiation therapy; Thymic malignancies

Indexed keywords

ADAPTIVE RADIATION THERAPY; CANCER RADIOTHERAPY; FOUR DIMENSIONAL IMAGING; HUMAN; IMAGING SYSTEM; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; PROTON RADIATION; REVIEW; THREE DIMENSIONAL IMAGING; THYMUS CANCER;

EID: 77957608978     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f20ea2     Document Type: Article

References (26)

1. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unre-sectable malignant thymomas: final report. Lung Cancer 2004;44:369-379.
2. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49:1486-1493.
3. Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 2008;70:707-714.
4. Gayed IW, Liu HH, Wei X, et al. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol 2009;4:179-184.
5. Abratt RP, Morgan GW, Silvestri G, et al. Pulmonary complications of radiation therapy. Clin Chest Med 2004;25:167-177.
6. Purdy JA. Current ICRU definitions of volumes: limitations and future directions. Semin Radiat Oncol 2004;14:27-40.
7. Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 1997;15:3093-3099.
8. Mornex F, Resbeut M, Richaud P, et al. Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. The FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. Int J Radiat Oncol Biol Phys 1995;32:651-659.
9. Nakao T, Kanaya H, Namura M, et al. Complete atrioventricular block following radiation therapy for malignant thymoma. Jpn J Med 1990; 29:104-110.
10. Uematsu M, Yoshida H, Kondo M, et al. Entire hemithorax irradiation following complete resection in patients with stage II-III invasive thymoma. Int J Radiat Oncol Biol Phys 1996;35:357-360.
11. Latz D, Schraube P, Oppitz U, et al. Invasive thymoma: treatment with postoperative radiation therapy. Radiology 1997;204:859-864.
12. Hartford AC, Palisca MG, Eichler TJ, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). Int J Radiat Oncol Biol Phys 2009;73:9-14.
13. Nieder C, Schill S, Kneschaurek P, et al. Comparison of three different mediastinal radiotherapy techniques in female patients: impact on heart sparing and dose to the breasts. Radiother Oncol 2007;82:301-307.
14. Fang LC, Komaki R, Allen P, et al. Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:108-116.
15. Wilson EM, Joy Williams F, Lyn BE, et al. Comparison of two dimensional and three dimensional radiotherapy treatment planning in locally advanced non-small cell lung cancer treated with continuous hyperfractionated accelerated radiotherapy weekend less. Radiother Oncol 2005;74:307-314.
16. Liao ZX, Komaki RR, Thames HD Jr, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010;76:775-781.
17. Onimaru R, Shirato H, Fujino M, et al. The effect of tumor location and respiratory function on tumor movement estimated by real-time tracking radiotherapy (RTRT) system. Int J Radiat Oncol Biol Phys 2005;63: 164-169.
18. Seppenwoolde Y, Shirato H, Kitamura K, et al. Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int J Radiat Oncol Biol Phys 2002;53: 822-834.
19. Redmond KJ, Song DY, Fox JL, et al. Respiratory motion changes of lung tumors over the course of radiation therapy based on respiration-correlated four-dimensional computed tomography scans. Int J Radiat Oncol Biol Phys 2009;75:1605-1612.
20. Vlachaki M, Castellon I, Leite C, et al. Impact of respiratory gating using 4-dimensional computed tomography on the dosimetry of tumor and normal tissues in patients with thoracic malignancies. Am J Clin Oncol 2009;32:262-268.
21. George R, Ramakrishnan V, Siebers JV, et al. Investigation of patient, tumour and treatment variables affecting residual motion for respiratory-gated radiotherapy. Phys Med Biol 2006;51:5305-5319.
22. Britton KR, Starkschall G, Liu H, et al. Consequences of anatomic changes and respiratory motion on radiation dose distributions in conformal radiotherapy for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;73:94-102.
23. Spoelstra FO, Pantarotto JR, van Sornsen de Koste JR, et al. Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial. Int J Radiat Oncol Biol Phys 2009;75:1092-1097.
24. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65: 1087-1096.
25. Chera BS, Rodriguez C, Morris CG, et al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 2009;75:1173-1180.
26. Zhang X, Li Y, Pan X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 2010;77:357-366.